TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2404514

Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin cream applied once daily for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo applied once daily for 12 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin cream
Number of subjects: 20
Study: 6996627

Group type: EXPERIMENTAL
Intervention: Guanfacine, 1 mg twice daily p.o.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Alpha-methyldopa, 250 mg three times a day p.o.
Number of subjects: 30
Study: 29486750

Group type: EXPERIMENTAL
Intervention: Game-based exercise training program
Number of subjects: 112

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 112
Study: 26643326

Group type: EXPERIMENTAL
Intervention: Paritaprevir (NS3/4A inhibitor boosted with ritonavir) and Ombitasvir (NS5A inhibitor)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Paritaprevir and Ombitasvir
Number of subjects: 436
Study: 24676506

Group type: EXPERIMENTAL
Intervention: TEO (high-definition 2-D transanal endoscopic operation)
Number of subjects: 34

Group type: COMPARATOR
Intervention: TEM (transanal endoscopic microsurgery)
Number of subjects: 34
Study: 23467861

Group type: EXPERIMENTAL
Intervention: 10 mL epidural injection of 0.1% ropivacaine
Number of subjects: 66

Group type: COMPARATOR
Intervention: 10 mL of 0.9% saline solution (control)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 66
Study: 20414043

Group type: EXPERIMENTAL
Intervention: Citalopram (CT) 20 mg iv over 120 min
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (saline iv over 120 min)
Number of subjects: 36
Study: 19105013

Group type: EXPERIMENTAL
Intervention: Educational program delivered by a lay health advisor
Number of subjects: 851

Group type: COMPARATOR
Intervention: Physician letter and brochure about cervical cancer screening (control group)
Number of subjects: 851
Study: 16831654

Group type: EXPERIMENTAL
Intervention: Biodegradable polylactide pins
Number of subjects: 164

Group type: COMPARATOR
Intervention: Standard metal mini-fragment implants
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Both treatment methods
Number of subjects: 164
Study: 12796070

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once-daily subcutaneous injection for 19 to 23 days
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 656

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 656
Study: 10229588

Group type: EXPERIMENTAL
Intervention: Intratympanic gentamicin infusion (26.7 mg/mL, 0.2 to 0.3 mL)
Number of subjects: 32
Study: 8911453

Group type: EXPERIMENTAL
Intervention: Metronidazole at a concentration of 5 mg/ml
Number of subjects: 0
Study: 1663391

Group type: EXPERIMENTAL
Intervention: Guar breads
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control breads
Number of subjects: 0
Study: 6127965

Group type: EXPERIMENTAL
Intervention: 131-iodine (n = 16)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Propylthiouracil (n = 20)
Number of subjects: 36
Study: 3925751

Group type: EXPERIMENTAL
Intervention: High zinc supplement
Number of subjects: 105

Group type: COMPARATOR
Intervention: Different zinc supplement groups
Number of subjects: 105

Group type: COMPARATOR
Intervention: Copper dose groups
Number of subjects: 105
Study: 31118449

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFCA)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 3D mapping-guided cryoablation
Number of subjects: 210
Study: 30045593

Group type: EXPERIMENTAL
Intervention: Tramadol (active treatment)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 29
Study: 26817469

Group type: EXPERIMENTAL
Intervention: COX inhibitor (acetaminophen, 4 gram/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 24671720

Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) supplementation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 22206630

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 25
Study: 20415341

Group type: EXPERIMENTAL
Intervention: Feedback actigraphy
Number of subjects: 0
Study: 18581975

Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) to common inhalant allergens
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Allergen-specific IgE (asIgE) testing
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Allergen-specific IgE (asIgE) testing for food allergens
Number of subjects: 156

Group type: COMPARATOR
Intervention: Comparison of current findings with previous study
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) in town dwellers
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) in rural areas
Number of subjects: 156
Study: 15621380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Gabapentin (1800 mg/day)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg/day)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Gabapentin-Rofecoxib combination (1800/50 mg/day)
Number of subjects: 110
Study: 12162469

Group type: EXPERIMENTAL
Intervention: Enalapril (low dose: 0.625 or 1.25 mg, middle dose: 2.5 or 5 mg, high dose: 20 or 40 mg)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Enalapril (middle and high dose)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 10078669

Group type: EXPERIMENTAL
Intervention: Atropine (15 microg/kg)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Glycopyrrolate (10 microg/kg)
Number of subjects: 93
Study: 7750159

Group type: EXPERIMENTAL
Intervention: 90 mg DHC
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 50 mg tramadol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2406406

Group type: EXPERIMENTAL
Intervention: Continued breast-feeding during rotaviral gastroenteritis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactose-free soya feeds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cow's milk-formula feeds
Number of subjects: 0
Study: 6989549

Group type: EXPERIMENTAL
Intervention: Low abrasivity paste containing 0.8% sodium monofluorophosphate
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Conventional abrasivity paste containing 0.8% sodium monofluorophosphate
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Low abrasivity non-fluoride paste
Number of subjects: 1106
Study: 30333407

Group type: EXPERIMENTAL
Intervention: Endoscopic Band Ligation (EBL)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Endoscopic Clipping (EC)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Risk factor analysis
Number of subjects: 135
Study: 29998139

Group type: EXPERIMENTAL
Intervention: Group care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Individual care
Number of subjects: 60
Study: 26631343

Group type: EXPERIMENTAL
Intervention: Needle fasciotomy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Collagenase injection
Number of subjects: 93
Study: 24665646

Group type: EXPERIMENTAL
Intervention: Post-core crown restoration
Number of subjects: 30
Study: 21979272

Group type: EXPERIMENTAL
Intervention: 6-month physical therapist-prescribed balance and strength home exercise program
Number of subjects: 165

Group type: COMPARATOR
Intervention: Usual activities (control group)
Number of subjects: 165
Study: 19158209

Group type: EXPERIMENTAL
Intervention: 3 g cinnamon
Number of subjects: 15

Group type: COMPARATOR
Intervention: 1 g cinnamon
Number of subjects: 15
Study: 17541317

Group type: EXPERIMENTAL
Intervention: RISKO Heart Hazard Appraisal to quantify CAD risk factor burden
Number of subjects: 152
Study: 15562929

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 5
Study: 11078906

Group type: EXPERIMENTAL
Intervention: Reduced training (1 session/wk)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Reduced training (2 or 1 session(s)/wk)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Detraining (0 session/wk)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 21
Study: 9338047

Group type: EXPERIMENTAL
Intervention: Deflazacort (DFZ)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Prednisone (PDN)
Number of subjects: 72
Study: 8403174

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg.kg‐1
Number of subjects: 72

Group type: COMPARATOR
Intervention: Thiopentone 5 mg.kg‐1
Number of subjects: 72
Study: 2943994

Group type: EXPERIMENTAL
Intervention: Albuterol (beta-2 adrenergic agent)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (anticholinergic agent)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Albuterol followed by Ipratropium bromide
Number of subjects: 11

Group type: COMPARATOR
Intervention: Ipratropium bromide followed by Albuterol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31944869

Group type: EXPERIMENTAL
Intervention: VAULT treatment (3 target words/90 doses per word per session)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: VAULT treatment (6 target words/45 doses per word per session)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No-treatment condition
Number of subjects: 24
Study: 30306222

Group type: EXPERIMENTAL
Intervention: Continuous moderate-intensity exercise (CMIE)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Low-volume high-intensity interval exercise (LV-HIIE)
Number of subjects: 27
Study: 28164208

Group type: EXPERIMENTAL
Intervention: Chronic hemodialysis patients
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Older patients (≥75 years)
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Albumin levels
Number of subjects: 714
Study: 25974146

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) program, 8 sessions, guided internet-based CBT for students identified as actively suicidal or at higher risk.
Number of subjects: 3244

Group type: EXPERIMENTAL
Intervention: CBT program participants (163 out of 503 offered, 32%)
Number of subjects: 3244

Group type: COMPARATOR
Intervention: Control group (students who did not participate in CBT)
Number of subjects: 3244

Group type: COMPARATOR
Intervention: Overall population screened
Number of subjects: 3244
Study: 24019074

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control
Number of subjects: 121
Study: 21374657

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 641
Study: 18304211

Group type: EXPERIMENTAL
Intervention: α1-Adrenoceptor antagonists (blockers)
Number of subjects: 0
Study: 17175307

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) + CsA + prednisolone
Number of subjects: 41

Group type: COMPARATOR
Intervention: MMF + CsA + prednisolone
Number of subjects: 41

Group type: COMPARATOR
Intervention: CsA + AZA + prednisolone
Number of subjects: 41
Study: 14668957

Group type: EXPERIMENTAL
Intervention: Adjuvant external beam radiotherapy (RTx)
Number of subjects: 311

Group type: COMPARATOR
Intervention: No external beam radiotherapy (no RTx)
Number of subjects: 311
Study: 11081889

Group type: EXPERIMENTAL
Intervention: IRWSE + cold blood (CB)
Number of subjects: 67

Group type: COMPARATOR
Intervention: cold blood (CB)
Number of subjects: 67
Study: 9258475

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) and oral anticoagulant (group A)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) and ticlopidine (group B)
Number of subjects: 175
Study: 8337194

Group type: EXPERIMENTAL
Intervention: Group education program based on social learning theory and the 'Arthritis Self‐Management Course'
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group education program
Number of subjects: 0
Study: 2427845

Group type: EXPERIMENTAL
Intervention: Atenolol (1, 1, 2, and 4 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Celiprolol (1, 1, 2, and 4 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Atenolol and Celiprolol during exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 24
Study: 31791288

Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC) 10 g three times daily
Number of subjects: 170
Study: 29897951

Group type: EXPERIMENTAL
Intervention: Flashlight guidance
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control (no flashlight guidance)
Number of subjects: 121
Study: 28286995

Group type: EXPERIMENTAL
Intervention: Dates consumption
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (no dates consumption)
Number of subjects: 154
Study: 25787197

Group type: EXPERIMENTAL
Intervention: PCI with a sirolimus‐eluting stent
Number of subjects: 600

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 600
Study: 23228222

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NOR) added to multi-component smoking cessation intervention (CBT and NRT)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Placebo added to multi-component smoking cessation intervention (CBT and NRT)
Number of subjects: 425
Study: 21908175

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Befriending
Number of subjects: 62
Study: 18163419

Group type: EXPERIMENTAL
Intervention: Specific strength training for the affected muscle
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: General fitness training (leg bicycling with relaxed shoulders)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reference intervention without physical activity
Number of subjects: 48
Study: 17050869

Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m2 plus pemetrexed 500 mg/m2
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5 plus pemetrexed 500 mg/m2
Number of subjects: 78
Study: 12716335

Group type: EXPERIMENTAL
Intervention: Halita mouthwash (chlorhexidine, cetylpyridinium chloride, zinc lactate)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Halita mouthwash
Number of subjects: 40
Study: 11053331

Group type: EXPERIMENTAL
Intervention: Hypoxia (17.42% O(2))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normoxia (20.93% O(2))
Number of subjects: 8
Study: 7818061

Group type: EXPERIMENTAL
Intervention: Lignocaine-propofol combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoclopramide-propofol combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 3178907

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: D-penicillamine (DP)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 29863392

Group type: EXPERIMENTAL
Intervention: Group Questionnaire (GQ) + Outcome Questionnaire-45 (OQ-45)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Outcome Questionnaire-45 (OQ-45)
Number of subjects: 430
Study: 28251755

Group type: EXPERIMENTAL
Intervention: Cardiac-specific troponin I
Number of subjects: 1653

Group type: EXPERIMENTAL
Intervention: Endothelin-1
Number of subjects: 1653

Group type: EXPERIMENTAL
Intervention: Several biomarkers (individually and in combination)
Number of subjects: 1653
Study: 25042595

Group type: EXPERIMENTAL
Intervention: DAV132
Number of subjects: 18

Group type: COMPARATOR
Intervention: FAC
Number of subjects: 18

Group type: COMPARATOR
Intervention: Water
Number of subjects: 18
Study: 23593631

Group type: COMPARATOR
Intervention: acid etching + Single Bond (SB) (control)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: acid etching + SB + Nd:YAG laser irradiation (before adhesive curing)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: thermal etching with the Er:YAG laser + SB
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: thermal etching with the Er:YAG laser + SB + Nd:YAG laser irradiation (before adhesive curing)
Number of subjects: 56
Study: 21193287

Group type: EXPERIMENTAL
Intervention: Modified Manual Edema Mobilization (MEM) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional edema treatment
Number of subjects: 0
Study: 19661926

Group type: EXPERIMENTAL
Intervention: CISalt (1% sodium content)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Normal salt (8% or 1% sodium content)
Number of subjects: 248
Study: 17922975

Group type: EXPERIMENTAL
Intervention: irinotecan/cisplatin (IP)
Number of subjects: 535
Study: 14709456

Group type: EXPERIMENTAL
Intervention: Midazolam (30 ng.mL(‐1) target effect site concentration)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 11167476

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 90
Study: 9514561

Group type: EXPERIMENTAL
Intervention: Capsaicin administered subcutaneously in the right forehead to evoke a burning painful sensation.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Capsaicin administration
Number of subjects: 7
Study: 7593655

Group type: EXPERIMENTAL
Intervention: 50% sucrose solution (g/100 mL)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 57
Study: 2181031

Group type: EXPERIMENTAL
Intervention: Vaccine (50 micrograms) administered intramuscularly at weeks 0, 4, and 22
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo administered intramuscularly at weeks 0, 4, and 22
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Vaccine (50 micrograms)
Number of subjects: 161
Study: 282028

Group type: EXPERIMENTAL
Intervention: Wardill-Kilner repair (Group I)
Number of subjects: 47

Group type: COMPARATOR
Intervention: von Langenbeck repair (Group II)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: von Langenbeck repair with superiorly based pharyngeal flap (Group III)
Number of subjects: 47
Study: 31915983

Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment (number of immunosuppressants)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Degree of comorbidity
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Intensity of inflammatory activity
Number of subjects: 382
Study: 31166571

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray plus oral antidepressant
Number of subjects: 297

Group type: COMPARATOR
Intervention: Antidepressant plus placebo nasal spray
Number of subjects: 297
Study: 27599663

Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab 162 mg every week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab 162 mg every 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous tocilizumab 8 mg/kg every 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous tocilizumab every 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab every week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26504777

Group type: EXPERIMENTAL
Intervention: ELISA-IgM
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Hoffman, Pons, and Janer (HH)
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Kato-Katz (KK)
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: qPCR-serum
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: ELISA-IgG
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: IFT-IgM
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: All techniques except qPCR-serum
Number of subjects: 1222
Study: 23866917

Group type: EXPERIMENTAL
Intervention: Sequential stage-matched intervention targeting procurement and consumption of fruits, vegetables, salt, sugar, and oil; delivered over 1 year with strategies at 0, 6, and 12 months, including counselling sessions, telephonic reminders, and home visits.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group received information on recommended levels of intake of the five dietary components and general dietary information leaflets.
Number of subjects: 0
Study: 21311065

Group type: EXPERIMENTAL
Intervention: Carotid Angioplasty and Stenting (CAS)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 507
Study: 19827881

Group type: EXPERIMENTAL
Intervention: Riboflavin-fortified salt
Number of subjects: 22893

Group type: COMPARATOR
Intervention: Control group (no riboflavin-fortified salt)
Number of subjects: 22893
Study: 16205845

Group type: EXPERIMENTAL
Intervention: Lying position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Standing position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Various positions (crook lying, supine, sitting, standing)
Number of subjects: 20
Study: 14767169

Group type: EXPERIMENTAL
Intervention: Urea-containing gum
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Urea rinsing
Number of subjects: 11
Study: 11332061

Group type: COMPARATOR
Intervention: Lidocaine 0.5% with saline (3 mg.kg‐1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5% with clonidine (150 micrograms) (3 mg.kg‐1)
Number of subjects: 45
Study: 9202914

Group type: EXPERIMENTAL
Intervention: 20 mL of anaesthetic solution (0.5% bupivacaine with adrenaline 1:200,000 and 2% lignocaine)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 30 mL of anaesthetic solution (0.5% bupivacaine with adrenaline 1:200,000 and 2% lignocaine)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 40 mL of anaesthetic solution (0.5% bupivacaine with adrenaline 1:200,000 and 2% lignocaine)
Number of subjects: 90